Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 Life Science Investing
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 Life Science Investing
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer Life Science Investing
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Life Science Investing
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction Life Science Investing
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 Life Science Investing
